BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody

New composition of matter IP filed for chemically distinct, orally active, and highly potent small molecule APJ agonists

Read more at globenewswire.com